JeanMarie Guenot, President and CEO of Amphivena Therapeutics, has enjoyed a lustrous and successful career in the pharmaceutical industry. She has extensive management experience in the areas of cardiovascular disease, autoimmune diseases, neurology and ophthalmic diseases and oncology. She attended the University of California, earning a Ph.D. She also acquired an MBA from The Wharton School at the University of Pennsylvania. Dr. Jeanmarie Guenot received training in medicinal and physical chemistry and focused much of her attention on the semi-empirical and quantum mechanical methods for protein structure prediction, molecular dynamics and X-ray and NMR drug design.
JeanMarie Guenot began her career at Atlas Venture, where she constructed life science corporations and supervised venture capital investments. She also spent some time working as a scientist at Hoffman-La Roche, focusing on developing new drugs for inflammation, oncology, metabolic diseases and autoimmune diseases.
She created and ran the company SKS Ocular on linkedin.com, which is an ophthalmic company incubator dealing with therapeutics for macular degeneration, ocular inflammation and glaucoma, as well as a variety of drug delivery technologies. In 2013, she also worked for PDL BioPharma, where she was in charge of overseeing mergers, licensing, acquisitions and alliance management for their commercial product files. She was directly responsible for the Biogen Idec PDL 50:50 co-commercialization collaboration.
Amphivena Therapeutics was founded in 2012 and is based out of Wilmington, Delaware. Amphivena Therapeutics specializes in the development of antibodies for hematologic tumors. One of the company’s newest developed drug is AMV-564, which is designed to help treat acute myeloid leukemia. AMV-564 is still in its early phase, but is ready for clinical trials on Crunchbase. AMV-564’s large molecular size offers a significant advantage over other tinier monovalent bi-specific constructs.
JeanMarie Guenot received a BioBusiness Network Innovative Bio-Partening Award in 2005. And in 2006, she was honored with the Licensing Executives Society’s Deal of Distinction Award.